BIO Is Helping Companies Boost Minority Participation In Clinical Trials

BIO head Michelle McMurry-Heath discusses group’s efforts to increase enrollment of people of color in COVID-19 clinical trials and why New York’s task force to give second review to COVID-19 vaccines is “dangerous for patients.”

BIO President and CEO Michelle McMurray-Heath
BIO President & CEO Michelle McMurry-Heath • Source: Screenshot from FDLI annual conference

More from Clinical Trials

More from R&D